▶ 調査レポート

フローサイトメトリーの世界市場2021-2026:成長・動向・新型コロナの影響・市場予測

• 英文タイトル:Flow Cytometry Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

Mordor Intelligenceが調査・発行した産業分析レポートです。フローサイトメトリーの世界市場2021-2026:成長・動向・新型コロナの影響・市場予測 / Flow Cytometry Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026) / MRC2103C079資料のイメージです。• レポートコード:MRC2103C079
• 出版社/出版日:Mordor Intelligence / 2021年2月25日
• レポート形態:英文、PDF、125ページ
• 納品方法:Eメール(受注後2-3営業日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥484,500 (USD4,250)▷ お問い合わせ
  Team User¥541,500 (USD4,750)▷ お問い合わせ
  Corporate License¥855,000 (USD7,500)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査資料では、世界のフローサイトメトリー市場について調査し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品種類別(機器、キット・試薬、ソフトウェア、その他)分析、技術別(細胞由来フローサイトメトリー、ビード由来フローサイトメトリー)分析、用途別(腫瘍、創薬、疾患診断、幹細胞治療、臓器移植、血液、その他)分析、エンドユーザー別(病院・クリニック、学術・研究機関、製薬・バイオテクノロジー企業、その他)分析、地域別分析、競争状況、市場機会/将来の見通しなどを掲載しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・市場動向
・世界のフローサイトメトリー市場規模:製品種類別(機器、キット・試薬、ソフトウェア、その他)
・世界のフローサイトメトリー市場規模:技術別(細胞由来フローサイトメトリー、ビード由来フローサイトメトリー)
・世界のフローサイトメトリー市場規模:用途別(腫瘍、創薬、疾患診断、幹細胞治療、臓器移植、血液、その他)
・世界のフローサイトメトリー市場規模:エンドユーザー別(病院・クリニック、学術・研究機関、製薬・バイオテクノロジー企業、その他)
・世界のフローサイトメトリー市場規模:地域別
・競争状況
・市場機会/将来の見通し

The global flow cytometry market was valued at approximately USD 4,150 million in 2020 and it is expected to reach USD 6,682 million by 2026, registering a CAGR of nearly 8.1% during the forecast period.

The COVID-19 outbreak is expected to show the impact on the flow cytometry market. The increasing adoption of flow cytometry techniques in research activities and clinical trials has provided a wide range of growth opportunities for market players. In 2020, Cytek Biosciences Inc. supported researchers and clinicians around the world, studying the impact of the COVID-19 virus on human immune systems. The Cytek family fully supported researchers during this crucial period by providing technical assistance for their flow cytometers, Cytek Aurora, Cytek Athena, and Cytek Northern Lights systems

Cytek has also contributed several instruments to leading clinical laboratories in China for use in COVID-19 clinical research and diagnostic test development. The company attained clinical use certification in China in 2019 for their DxPTM Athena and Northern Lights CLC instruments (Flow cytometers), which has enabled them to support a growing list of clinical research institutions, including a hospital in the center of the pandemics in Wuhan.

The key factors propelling the market include the rise in the use of flow cytometry in stem cell research, the emergence and commercial application of new technologies in the field of flow cytometry, and the rise in the applications of flow cytometry in clinical research.

There is a significance of flow cytometry in clinical research that is fueling the demand for flow cytometry techniques in R&D departments of the healthcare sector. The current applications of flow cytometry in clinical research include – emphasizing immunophenotyping, enumerating reticulocyte and reticulated platelet, multiple drug resistance assays, cell function assays, and apoptosis. The developments in immunology and other areas of cancer research have mainly contributed to the use of flow cytometry. Immunophenotyping, or characterization of cell subpopulations based on differentiation antigens, is the most well-recognized area in flow cytometry. Immunophenotyping is used clinically for the diagnosis and sub-classification of leukaemia and lymphoma, diagnosis of primary immunodeficiency disorders, and enumeration of stem cells in peripheral blood, among other applications.

The increasing incidences of HIV and cancer statistics show a significant unmet opportunity in cancer and AIDS diagnostics. There is a large void in diagnostics accessibility, particularly in the developing regions. Consequently, the increasing incidences of HIV AIDS, and cancer can be considered a significant growth opportunity for the flow cytometry market.

Key Market Trends

Stem Cell Therapy is Expected to Hold the Largest Market Share by Application

Flow cytometry is required to identify, characterize, and isolate stem cells for research and activities due to their ability to rapidly perform quantitative measurements on single cells, within a heterogeneous cell population.

Stem cell-based therapies are being suggested to reduce or treat COVID-19. Several companies and universities are involved in research studies associated with stem cells. For instance, in August 2020, the University of Minnesota Institute used mesenchymal stem cells (MSCs) for the patients affected by COVID-19 and lung failure. Thus, the rising research activities in this field will drive the demand for flow cytometers.

The major factors responsible for the large market share include the extensive use of flow cytometry for effective diagnosis and early detection of numerous diseases that have helped the market to gain immense shares. The growing market penetration in stem cell research, adoption of recombinant DNA technology for antibody production, and evolution of tandem flow cytometry technologies are expected to offer growth opportunities for the key players operating in the flow cytometry market.

In contrast to methods, such as Western blot and cellular imaging, multicolor flow cytometry enables researchers to interrogate heterogeneous cell populations and analyze their subpopulations. By multiple fluorescent labeled antibodies, researchers can obtain robust data & population-based statistics on differentiating stem cell cultures and can isolate stem cells and their derivatives from primary tissue and diverse in-vitro populations.

Flow cytometry has also found many applications in drug discovery to understand the drugs mechanism of action, which may also contribute to the market growth.

North America Dominates the Market and is Expected to Continue its Lead over the Forecast Period

North America is expected to dominate the flow cytometry market and is projected to continue over the forecast period. In addition, the rising focus of companies in the expansion of novel products that are anticipated to offer new growth opportunities, which may propel the market growth.

In the North American region, the united states hold the major share, this is mainly due to the factors such as the increasing burden of cancer. According to the National Cancer Institute data In 2020, an estimated 1,806,590 new cases of cancer will be diagnosed in the United States and 606,520 people will die from the disease. The common cancers in the United States are breast cancer, lung cancer, prostate cancer, colon and rectum cancer, bladder cancer, and skin cancer.

The role of flow cytometry to determine the prognosis in patients with cancer has become increasingly important with the advent of assays for the detection of disease & assessment of drug resistance.

Furthermore, companies, like Sysmex are focusing on the launch of new products, For instance, in June 2020, Sysmex America, Inc., a leading diagnostic solutions company announced the availability of its XF-1600 flow cytometer. This will provide laboratories with improved flexibility and efficiency for a wide range of applications. Hence, owing to these factors, the market is expected to grow at a faster pace.

Competitive Landscape

The flow cytometry market is considered highly consolidated due to the presence of very few players in the market. These players are holding a huge share of the market and are likely to remain in a similar competitive environment for the next few years. Key market players in the market are Becton, Dickinson and Company, Danaher (Beckman Coulter), Merck KGaA, Bio-Rad Laboratories, Luminex Corporation, etc.

The rising importance of product development and the rise in R&D activities are projected to encourage the growth of the flow cytometry market. In 2019, Agilent technologies introduced its new product from recently acquired ACEA Biosciences, at the 34th Congress of the International Society for Advancement of Cytometry, CYTO 2019 Congress, being held June 2019 in Vancouver, Canada. The Agilent NovoCyte Advanteon Flow Cytometer is one of the most sensitive cell analyzers available on the market. Flow cytometers are integral to basic research, drug discovery, and clinical diagnostics. In the coming years, few other players are expected to enter the market, which may fuel the market growth.

Reasons to Purchase this report:

– The market estimate (ME) sheet in Excel format
– 3 months of analyst support

レポート目次

1 INTRODUCTION
1.1 Study Deliverables
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Adoption of Flow Cytometry in Stem Cell Research
4.2.2 Increasing Applications of Flow Cytometry in Clinical Research
4.3 Market Restraints
4.3.1 Lack of Awareness about the Potential Benefits of Flow Cytometry Techniques
4.3.2 High Cost of the Equipment
4.4 Industry Attractiveness – Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Instrument
5.1.2 Kit and Reagent
5.1.3 Software
5.1.4 Other Product Types
5.2 By Technology
5.2.1 Cell-based Flow Cytometry
5.2.2 Bead-based Flow Cytometry
5.3 By Application
5.3.1 Oncology
5.3.2 Drug Discovery
5.3.3 Disease Diagnosis
5.3.4 Stem Cell Therapy
5.3.5 Organ Transplantation
5.3.6 Hematology
5.3.7 Other Applications
5.4 By End User
5.4.1 Hospitals and Clinics
5.4.2 Academia and Research Institutes
5.4.3 Pharmaceutical and Biotechnology Companies
5.4.4 Other End Users
5.5 Geography
5.5.1 North America
5.5.1.1 United States (By Product, By Technology, By Application, and By End User)
5.5.1.2 Canada (By Product, By Technology, By Application, and By End User)
5.5.1.3 Mexico (By Product, By Technology, By Application, and By End User)
5.5.2 Europe
5.5.2.1 Germany (By Product, By Technology, By Application, and By End User)
5.5.2.2 United Kingdom (By Product, By Technology, By Application, and By End User)
5.5.2.3 France (By Product, By Technology, By Application, and By End User)
5.5.2.4 Italy (By Product, By Technology, By Application, and By End User)
5.5.2.5 Spain (By Product, By Technology, By Application, and By End User)
5.5.2.6 Rest of Europe (By Product, By Technology, By Application, and By End User)
5.5.3 Asia-Pacific
5.5.3.1 China (By Product, By Technology, By Application, and By End User)
5.5.3.2 Japan (By Product, By Technology, By Application, and By End User)
5.5.3.3 India (By Product, By Technology, By Application, and By End User)
5.5.3.4 Australia (By Product, By Technology, By Application, and By End User)
5.5.3.5 South Korea (By Product, By Technology, By Application, and By End User)
5.5.3.6 Rest of Asia-Pacific (By Product, By Technology, By Application, and By End User)
5.5.4 Middle East and Africa
5.5.4.1 GCC (By Product, By Technology, By Application, and By End User)
5.5.4.2 South Africa (By Product, By Technology, By Application, and By End User)
5.5.4.3 Rest of Middle East and Africa (By Product, By Technology, By Application, and By End User)
5.5.5 South America
5.5.5.1 Brazil (By Product, By Technology, By Application, and By End User)
5.5.5.2 Argentina (By Product, By Technology, By Application, and By End User)
5.5.5.3 Rest of South America (By Product, By Technology, By Application, and By End User)

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Becton, Dickinson and Company
6.1.2 Danaher (Beckman Coulter)
6.1.3 Merck KGaA
6.1.4 Bio-Rad Laboratories
6.1.5 Luminex Corporation
6.1.6 Miltenyi Biotech
6.1.7 Sysmex Partec GmbH
6.1.8 Agilent Technologies
6.1.9 ThermoFisher Scientific
6.1.10 Sony Biotechnology Inc.
6.1.11 BioMerieux S.A

7 MARKET OPPORTUNITIES AND FUTURE TRENDS